Wertaschnigg D, Rolnik DL, Nie G, et al. - Serum levels of growth‐differentiation factor‐15 (GDF‐15) at three different gestational ages were compared between asymptomatic women who subsequently developed preterm or term PE and healthy controls. Researchers conducted this case–control study drawn from a prospective observational study on adverse pregnancy outcomes in women attending for their routine second‐ and third‐trimester hospital visits. A commercial GDF‐15 enzyme‐linked immunosorbent assay was used to determine serum GDF‐15 in 300 samples: 120 samples at 19–24 weeks of gestation, 120 samples at 30–34 weeks and 60 samples at 35–37 weeks. An increase in GDF‐15 values was noted with gestational age. Analysis revealed no value of serum GDF‐15 levels at 19–24 or 35–37 weeks of gestation for predicting preterm or term PE. Higher GDF‐15 levels are identified at 30–34 weeks in women who subsequently develop preterm PE, however, the difference is small and GDF‐15 does not seem valuable in clinical practice when used in isolation.